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1. Introduction
Autism is one of a group of pervasive developmental disorders and is characterised by qual‐
itative impairments in communication and social interactions and by stereotyped behav‐
iours and interests. Abnormal development is present before the age of 3 years. A quarter of
affected children show developmental regression with loss of acquired skills. One third of
children with autism have epilepsy and three quarters have mental retardation. Only 15 %
of adults with autism lead independent live. Twin and family studies suggest that most cas‐
es of autism occur because of combination of genetics factors [1]. Concept of autism has been
broadened the last few years from early infantile autism to an autistic spectrum and related
communication disorders are grouped together under pervasive developmental disorders or
autistic spectrum disorders. People with an autistic disorder have severe difficulties in the
integration of perceived in social stimuli into a meaningful entity. More than two people
with autistic disorder are also mentally retarded. Autism cannot be cured but adequate in‐
tervention can significantly improve the quality of life people with this disorder [2].
The American Psychiatric Association´s last version of the Diagnostic and Statistical manual
of Mental Disorders identifies within pervasive developmental disorders five subgroups:
a. autistic disorder,
b. Rett syndrome
c. childhood disintegrative disorder
d. Asperger's disorder and
e. pervasive developmental disorder.
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Prenatal exposure to infection and subsequent inflammatory responses have been implicat‐
ed in the etiology of autism and schizophrenia [3]. Children with autism are vulnerable to
anxiety. Also, higher levels of repetative behaviours were associated with more anxiety [4].
Autism is a pervasive developmental disorder characterised by impairment in social interac‐
tion and communication, with unusual behaviour [5].
From the previous 4 per 10,000 people, today’s prevalence estimates range from 0.6 to
around 1% [6].
The onset of autistic disorder is before the age of 3 years and is four to five times more fre‐
quent in boys than in girls. Girls with autism are more likely to have more severe mental
retardation. The causes of autism spectrum disorders are unknown, although genetic and
environmental influence have been implicated. There is increasing evidence that people
with autism spectrum disorder have abnormalities in the serotonergic system [7].
There are limited options for pharmacological therapeutic interventions in children with au‐
tism disorders and some studies showed that risperidone as an atypical antipsychotic may
be in effective for the treatment of people with autism and intellectual disabilities [8].
The primary models of treatment are non pharmacological interventions that include inter‐
vention models such as applied behaviour analysis and developmental and structured
teaching. The main role of pharmacological interventions is limited to treating symptoms
that may be interfering with a child´s ability to learn or function within a particular environ‐
ment [9].
The prevalence of prescription medications for children with autism is high. Survey indi‐
cates that one-half to two-thirds are prescribed at least one medication of any type and
about 45% are prescribed at least one psychotropic medication [10-11].
The most commonly prescribed psychotropic medications are antidepressants, stimulants
and antipsychotics. The reported prevalence of anticonvulsant medications is approximately
5% among children with autistic disorders and 11-13% among individuals across the life
course [12-13].
Atypical neuroleptics have been showed to be useful in the treatment of behavioral symp‐
toms in autism. Attention deficit and hyperactivity disorder medications may be affective
for countering the additional features of hyperactivity and short attention span. Antiepilep‐
tic drugs for epilepsy and bipolar disorder (Valproat etc.) and selective serotonin reuptake
inhibitors have shown promising results for depression [14].
One of the most frequently reported behavioral concerns among children with autism spec‐
trum disorder is high rates of activity and inattention, symptoms that are often associated
with attention deficit hyperactivity disorder [15]. The most studied antipshychotic drugs in‐
clude haloperidol and risperidone [8].
In low dosages, they have been shown to reduce repetitive behaviours (stereotypes) and so‐
cial withdrawal, as well as a number of related symptoms, such as a hyperactivity, aggres‐
sion, self-abuse behavior, liability of mood and irritability. All the listed symptoms have
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appeared in adult patients with schizophrenia, where also with the application of atypical
antipsychotics may affect on described clinical picture [16].
70 % of children have mild to moderate learning disability, the remaining 30 % with normal
IQ are classified as either high-functioning autism (with language difficulties) or Asperger´s
syndrome (with normal language). 1-2 % of those with autism have a normal life; 5 to 20 %
of those with autism have a borderline prognosis; but 70 % are totally dependent upon sup‐
port [17].
The both first and second-generation antipsychotics have shown safety and efficacy in short-
term and long-term studies in autism. Safety concerns associated with treatment include the
risk of drug-related dyskinesias, which is greater with the first-generation drugs (haloperi‐
dol, flufenazin), and the risk of weight gain and associated metabolic problems (increases in
glucose and lipids), which is greater with the second generation agents [18-19].
Risperidone has been shown to reduce repetitive behaviours and social withdrawal, hyper‐
activity, aggression, self-harm behaviour, temper tantrums, lability of mood and irritability
[17].
It is also has been proved helpful in treating children and adolescents with autism spectrum
disorders behavioural problems, conduct and bipolar disorder, Tourette’s syndrome and
schizophrenia [20].
Risperidone is a high potency antipsychotic with combined dopamine D2 and serotonin 5-
HT2 receptor antagonist properties, has been used to subdue aggressive or self-injurious be‐
haviours. Several reports have suggested that risperidone is effective in diminishing
aggressiveness, hyperactivity and self-injurious behaviour in children with autistic disorder.
For children with autism, lower dosages ranging from 0.5 to 4 mg per day are generally
used [21].
Treatment with atypical antipsychotic olanzapine also can be beneficial in alleviating some
behavioral symptoms (irritability, hyperactivity/noncompliance, lethargy), associated with
autism [22].
It is very important careful drug titration, usually start with half (½) or one (1) mg in the
morning, and then gradually increase the dose in order to prevent adverse effects [23].
It is important to educate parents of children about possible side effects of treatment with
antipsychotics. Most often side effects are feeling of stiffness, primarily in the neck and spi‐
nal muscles, sedation and weight gain, and in rare cases also galactorrhoea.
This approach can help parents to distinguish between symptoms of disorder and adverse
drug effects, reduce their anxiety and intimidation, and simultaneously upgrade compliance
and trust between parent and child. These medications are usually studied in adult schizo‐
phrenic patients, and there are frequent dilemmas on the use of this group of drugs in chil‐
dren. It is important to always take into account the adverse effects of this group of drugs,
time to inform parents about them and have continuous monitoring of children. We have
noticed that is often required professional assistance to parents of such children, because of
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the constant confrontation with difficulties and unpredictable course of illness and fear of
the uncertain future of their children.
2. Medical options for children and adolescents
Atypical antypsichotics
Atypical antipsychotics (AAPs) are a group of drugs originally developed to treat psychosis.
The group includes compounds brought to the market over the past 10 years as safer and
better tolerated alternatives to the existing „typical“ antipsychotics. In this group are: cloza‐
pine, risperidone, olanzapine, quetiapine, ziprasidone and aripriprazole. The target symptoms for
pharmacotherapy with AAP typically include aggression, self-injury, property destruction
or severe tantrums. Those drugs have lower risk of inducing neurological side effects such
as parkinsonism in the short-term and perhaps tardive dyskinesia in the long-term. These
newer compounds have been also reported to improve the negative symptoms of schizo‐
phrenia (abulia, avolition, flat affect) there is an interest in the notion that this may be rele‐
vant to the social withdrawal and lack of spontaneous interaction in autism. The reduced
occurence of dyskinesias and the improvement in negative symptoms of schizophrenia may
be related to the dual action of five-hydroxytryptamine (5-HT) to dopamine (DA) receptor
blockade [24]. The lower use of clozapine in autism probably reflects concerns about the risk
of blood dysplasia and seizures that are associated with the drug. Additionally, frequent
blood tests should be required to monitor for agranulocytosis, which can be challenging in
children with autism [25]. Risperidone has high affinities for DA D2-D4, 5HT2A, 5-HT2C re‐
ceptors [26].
It is an atypical antipsychotic (serotonin-dopamine antagonist: second generation antipsy‐
chotic) and also mood stabilizers. Risperidone blocks dopamine 2 receptors, reducing positive
symptoms of psychosis and stabilizing affective symptoms. They also block serotonin 2A re‐
ceptors causing enhancement of dopamine release in certain brain regions and thus reduc‐
ing motor side effects and possibly improving cognitive and affective symptoms.
Interactions at a myriad of other neurotransmitter receptors may contribute to risperidone's
efficacy. Alpha 2 antagonist properties may contribute to antidepressant actions. According
to Food and Drug Administration, risperidone is commonly prescribed for: schizophrenia
ages 13 and older, delaying relapse in schizophrenia, other psychotic disorders, acute mania,
mixed mania, autism related irritability in children ages 5 to 16, bipolar depression, behavio‐
ral disturbances in children and adolescents and disorders associated with problems with
impulse control [27]. Usual dosage range is 2 to 8 mg per day orally for acute psychosis and
bipolar disorder, but 0.5 to 2.0 mg per day orally for children and elderly. It is the most fre‐
quently used atypical antipsychotic in children and adolescents [28].
Research on risperidone shows it to be effective in treating aggressive behaviour in patient
population. Also, great improvements have been shown on the verbal communication, ap‐
perception and behavioural symptoms [29].
A large number of papers showed that risperidone is a good choice for autistic children with
the behavioral problems and irritability. Treatment with all newer antipsychotics was well
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tolerated with low rates of extrapyramid side effects and serious adverse effects. There is
evidence that autistic children and adolescents may be even more prone to weight gain with
antipsychotic treatment then patients with general psychiatric conditions. This may occur
because these individuals often have less autonomy and ability to take control of appetite,
food intake and exercise levels to prevent weight gain [30-31]. Risperidone was found to be
more effective than haloperidol in the treatment of behavioral symptoms, impulsivity, lan‐
guage skills, and impaired social relations in children with autistic disorders. Comparing
two groups children with autism, there was a greater increase of prolactin in the risperidone
group, while alanine aminotransferase had further increased in group that was treated with
haloperidol. Also sensory motor behaviours and language at the end of the study showed
that sensory motor skills and language subscales scores decreased in the group that was
treated with risperidone [32]. With use of risperidone in our Department we achieved re‐
duction of psychomotoric symptoms and reduction of hetero-aggressive and self-destructive
behaviours and also improvement in contact with his surroundings. Research on the use of
risperidone in the treatment of autistic children in Croatia is rare, given the limited use of
risperidone in children younger than 15 years, the question arises about the need to expand
the scope of application of risperidone in younger age groups (5).
Many studies show the effectiveness of haloperidol in a variety of behavioral symptoms in
autistic children. Haloperidol is conventional antipsychotic (neuroleptic, butyrophenone,
dopamine 2 antagonist) and according to Food and Drug Administration approved for:
manifestation of psychotic disorders, tics and vocal ultrances, in second-line treatment of se‐
vere behaviour problems in children of combative, explosive hyperexcitability, second-line
short-treatment of hyperactive children, treatment of schizophrenic patients who require
prolonged parenteral antipsychotic therapy, bipolar disorder, delirium, behavioral distur‐
bances in dementias. Haloperidol blocks dopamine 2 receptors, reducing positive symptoms
of psychosis and possibly combative behaviours. It blocks dopamine 2 receptors in the ni‐
grostriatal pathway, improwing tics and other symptoms in Tourette’s syndrome. There is
less evidence on the effectiveness of other typical antipsychotics. Haloperidol treatment of‐
ten causes side effects such as dystonic reactions and dyskinesis. Because of the risk of ex‐
trapyramidal symptoms, the use is limited only for refractory cases. The most often seen
side effects are: akathisia, neuroleptic-induced syndrome, parkinsonism, tardive dyskinesia,
tardive dystonia, galactorrhoea, amenorrhoea, dizziness, sedation, dry mouth, decreased
sweating, hypotension, tachycardia, hypertension, weight gain, tardive dystonia. Haloperi‐
dol is not intended for use under age 3. Initial oral dose is 0.5 mg/day; target dose 0.05-0.15
mg/kg per day for psychotic disorders and 0.05 to 0.075 mg/kg per day for nonpsychotic dis‐
orders [28]. Risperidone is from 2006. year approved by the FDA for the treatment of chil‐
dren older than 5 years. It helps in reducing the symptoms of irritability, aggression and
self-harm. The most frequent side effects are weight gain and sedation. Autism is a disorder
that lasts a lifetime. Autistic children with IQ higher than 70 and those that develope lan‐
guage communication ability to the fifth or seventh year have the best prognosis. Research
on autistic adults have shown that two-thirds of them remain seriously handicapped in
complete or partial dependence on caregivers. Only 1-2 percent of persons are capable for
independent life, including employment. Five to twenty percent of persons have nearly nor‐
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mal life. All study showed also some adverse events or adverse affects by using risperidone
such as: weight gain, somnolence, drowsiness, tremor, dyskinesia, rigidity. Also some au‐
thors reported a greater rise in prolactin levels in subjects which were treated by risperi‐
done. These results showed that also it was a greater rise in prolactin levels in subjects in the
risperidone compared with those in the placebo althought they did not report clinical events
such as gynecomastia or galactorrhoea, that could be elevated prolactin levels [33].
United Kingdom guidelines recommended maximum daily doses of between 2 and 3.5 mg
for children weighing under and over 45 kg, respectively. In practice many authorities rec‐
ommended using very small doses starting at 0.25 mg and increasing very slowly if re‐
quired.
Aripiprazole is the most recent addition to the list of available AAPs. Studies in adults with
schizophrenia have shown it to be an effective antipsychotic with a low risk of side effects
and causing reduced levels of weight gain [34]. Aripiprazole is dopamine partial agonist
(dopamine stabilizer, atypical antipsychotic, third generation antipsychotic) and commonly
prescribed for: schizophrenia ages 13 and older, maintaining stability in schizophrenia,
acute mania/mixed mania ages 10 and older, bipolar maintenance, depression, autism-relat‐
ed irritability in children ages 6 to 17, bipolar depresion, other psychotic disorders, disor‐
ders associated with problems with impulse control, behavioral disturbances in children
and adolescents. Theoretically increases dopamine output when dopamine concentrations
are low, thus improving cognitive, negative and mood symptoms. After treatment with ari‐
priprazole, children showed less irritability, hyperactivity, and stereotypes (repetitive, pur‐
poseless actions).
Notable side effects must be considered, however, such as weight gain, sedation, drooling,
and tremor (35).
By blocking alpha 1 adrenergic receptors it can cause dizziness, sedation and hypotension.
Partial agonist actions at dopamine 2 receptors can also cause nausea, occasional vomiting
and activating side effects. Mechanism of any possible weight gain is unknown; weight gain
is not common with aripriprazole and may have a different mechanism from atypical anti‐
psychotics for which weight gain is common or problematic. Usual dosage range is 15-30
mg/day, but children and patients which not acutely psychotic may need to be dosed lower
(2.5 -10 mg /day) in order to avoid akathisia and activation and for maximum tolerability.
Aripiprazole was efficacious in children and adolescents with irritability, associated with
autistic disorder and was generally safe and well tolerated. Also, it has been shown to be
efficacious and generally well tolerated in children and adolescents with schizophrenia and
bipolar mania [36-37]. Aripiprazole is approved for use in schizophrenia ages 13 and older,
manic/mixed episodes ages 10 and older and irritability associated with autism ages 6 to 17.
Clinical experience and early data suggest aripriprazole may be safe and effective for behav‐
ioral disturbances in children and adolescents, especially at lower doses. Children and ado‐
lescents using aripriprazole may need to be monitored more often than adults and may
tolerate lower doses better. Also, may be more risk of weight gain in children than in adults
[28]. Data in youth with autism and disruptive behaviour disorders, available only for some
antipsychotics, suggest greater weight gain, possibly due to less prior antipsychotic expo‐
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sure. Metabolic effects differ among second-generation antipsychotics, despite significant
weight gain with all studied agents, suggesting additional, weight-independent effects.
Pharmacological work indicates that antipsychotics polypharmacy increases the risk for obe‐
sity or any other cardiovascular, cerebrovascular or hypertensive adverse event [38].
Serotonin reuptake inhibitors (SRIs)
Repetitive behaviours are a core symptom domain in autism that has been linked to altera‐
tions in the serototonin system. While the selective serotonin-receptor inhibitor fluvoxamine
has been shown to be effective in adults with autism, as yet no published placebo controlled
trials with these agents document safety and efficacy in children with autism. Trials with
SRIs suggest benefits in adults with autism spectrum disorders. In the only double-blind
study of SRIs in adults with autism to date, McDougle et al. conducted a placebo controled
study on fluvoxamine and found that 53% patients were responders compared to placebo
group. Significant improvements in repetitive thoughts and behaviour, maldaptive behav‐
iour, aggression, social relatedness and language usage were reported. In contrast to this
adult trial of fluvoxamine, a subsequent trial in children and adolescents with autism con‐
ducted by the same group found poor response to fluvoxamine, only one of 18 responded,
while 14 had adverse effects [39]. To control the depressive symptoms are commonly used
fluoxetin, fluvoxamine and sertralin. These act to reduce repetitive, ritualized behaviours
and improvement in social skills. SRIs are prescribed for the treatment of co-morbidity asso‐
ciated with autistic spectrum disorders such as depression, anxiety and obsessive-compul‐
sive behaviours [40]. Several studies suggested that children may respond better to low
doses of SRIs specifically fluoxetine, than they did to fluvoxamine. Some of the FDA ap‐
proved drugs used to treat symptoms of autism that can be administrated to children above
the age of seven include fluoxetine, fluvoxamine, sertaline and clomipramine. Serotonin re‐
uptake inhibitors (SRIs) such as clomipramine, fluoxetine, fluvoxamine, sertraline, paroxetine, cit‐
alopram and escitalopram that inhibit the uptake at the presynaptic site.
Fluoxetine is selective serotonin reuptake inhibitor often classified as an antidepressant but it
is not only antidepressant. It is commonly prescribed for: major depressive disorder ages 8
and older, obsessive-compulsive disorder ages 7 and older, premenstrual dysphoric disor‐
der, bulimia nervosa, panic disorder, bipolar depression, treatment resistant depression in
combination with olanzapine, social phobia and posttraumatic stress disorder. Usual dosage
range is 20-80 mg for depression and 60 to 80 mg for bulimia. In children it is approved for
obsessive-compulsive disorder and it could be helpful in some autistic children with stero‐
types reactions. Adolescents often receive adult dose, but doses slightly lower for children.
Fluvoxamine is also selective serotonin reuptake inhibitor and commonly prescribed for ob‐
sessive-compulsive disorder, social anxiety disorder, depression, panic disorder, general‐
ized anxiety disorder, posttraumatic stress disorder and it was helpful for compulsive
behaviour and aggression as well as increased prosocial behaviour, in adults with autism,
who participated in a double-blind placebo controlled study [41].
In children fluvoxamine is approved for ages 8 to 17 for obsessive-compulsive disorder in
inital dose of 25 mg/day at bedtime, increase by 25 mg/day every 4 to 7 days. Mirtazapine is
an atypical antidepressant in that it posseses both serotoninergic and adrenergic activity.
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Study suggested that it can be helpfull for some children with autism for symptoms includ‐
ing aggression, self-injury, irritability, hyperactivity, anxiety, depression and insomia. Ad‐
verse effects were minimal and included increased appetite, irritability and transient
sedation [42]. Although SRIs may demonstrate therapeutic benefits in autism spectrum dis‐
orders, many studies suggest the need for additional randomized controlled trials. Also, giv‐
en the increased awareness of the dangers associated with SRIs induced activation and
agitation, the presence of these side effects in the autistic population warrants closer atten‐
tion to dosage, titration and subject selection issues [43].
No specific SRIs or dose range has been shown to improve a specific autistic symptom al‐
though some patients have demonstrated improvements. Benefits with these drugs in treat‐
ing functional impairments in autism have been observed. Response to therapy and adverse
effects are individualized. Current evidence does not support selection of one SRIs over an‐
other for any impairment associated with autism [44].
Tricyclic antidepressants
Autistic spectrum disorders is associated with restricted and/or sterotyped interests or be‐
haviours. Tricyclic antidepressants block noradrenaline and serotonin reuptake. Increasing
the availability of these neurotransmitters in the central nervous system. Through their im‐
pact on serotonin tricyclic antidepressants have been used in the treatment of autistic symp‐
toms and comorbidities in individuals with autism.
Clomipramine is a tricyclic antidepressant that inhibits the reuptake of both norepinephrine
and serotonin. It is commonly prescribed for obsessive-compulsive disorder, depression, se‐
vere and treatment-resistant depression, anxiety, insomnia, neuropathic pain/chronic pain.
It boosts neurotransmitters serotonin and noradrenaline, blocks serotonin reuptake pump,
presumably increasing noradrenergic neurotransmission. Notable side effects are: blurred
vision, constipation, urinary retention, increased appetite, dry mouth, nausea, diarrhoea,
heartburn, unusual taste in mouth, weight gain, fatigue, weakness, dizziness, sedation,
headache, anxiety, nervousness, restlessness, sexual dysfunction, sweating [28]. Clomipra‐
mine has been shown to reduce irritability, hyperactivity, inadequate eye contact and inap‐
propriate speech but also further research is required before tricyclic can be recommended
for treatment of autistic children [45]. In children and adolescents it is important to monitor
patients, particularly during the first several weeks of treatment, also not recommended for
use in children age 10.
Anticonvulsants
Anticonvulsants are commonly used in clinical practice in the treatment of autistic children
and adults. One in four people with autistic pervasive developmental disorder also have a
seizure disorder and usually treated with anticonvulsants such as carbamazepine, lamotri‐
gine, valproic acid. Lamotrigine is an anticonvulsant, mood stabilizer, voltage-sensitive so‐
dium channel antagonist and mostly prescribed for: maintenance treatment of bipolar
disorder, partial seizures in adults and children age 2 and older, bipolar depression, major
depressive disorder, etc. One of the common side effects is rash especially in children ages
under 12 and in children taking valproate. Very slow titration may reduce the incidence of
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skin rush. A study of lamotrigine in 28 children with autism showed no separation between
active drug and placebo on measures of stereotypes, lethargy, irritability, hyperactivity,
emotional reciprocity, sharing pleasures and in language and communication, socialization
and daily living skills noted after 12 weeks [46-47].
The goal of treatment is to alleviate symptoms and improve functioning. If it starts early in‐
tensive programs of education and behavioral therapy, can achieve for the child reaches a
certain level of independence and gain some social skills. Available pharmacotherapeutic
agents are not sufficiently effective for the treatment of the basic symptoms of autistic spec‐
trum. These can help in alleviating comorbid symptoms as a support to the educational, be‐
havioral and cognitive measures. Commonly treated pharmacologically, are the attention
deficit, hyperactivity, mood disorders, (anxiety, depression), obsessive-compulsive symp‐
toms, irritability, aggression, propensity for self-harm and sleep disorders. British study
from 2004. year by authors Emerson E. and Hatton C, (from Institute for Health Research,
Lancaster University, Lancaster UK), conducted on 68 adults whit autism diagnosed before
the 1980., with an IQ above 50 is shown following: twelve percent achieved a higher level of
independence, ten percent have some friends and are generally employed, but they need
support to some extent, nineteen percent have some independence, but generally live at
home and they need significant support with the supervision of daily life, forty-six percent
require professional, residential care in the specialized institutions for autistic spectrum dis‐
order, with high levels of support and very limited autonomy, while twelve percent have a
need for high levels of hospital care.
Electroconvulsive therapy /ECT
ECT is considered as a safe, effective and life-saving treatment in people mainly adults who
suffer from affective disorders, acute psychosis and catatonia. There are recent speculations
that certain types of autism may be the earliest expression of catatonia and that both disor‐
ders have identical risk factors. ECT may improve autism and if started early enough, may
prevent further development of autistic symptoms in some children. Researched area that
may support the hypothesis that ECT is effective in autism should be pursued [48]. Electro‐
convulsive therapy should be considered a potentially useful intervention in cases with au‐
tistic disorder and a severe comorbid affective disorder.
Acupunture
Acupuncture which involves the use of needles or pressure to specific points on the body, is
used widely in Traditional Chinese medicine and increasing within a western medical para‐
digm. Also, it has been sometimes used as a treatment aimed at improving autism spectrum
disorders symptoms and outcomes. Adverse effects noted included bleeding, crying due to
fear or pain of life [49].
Neurofeedback
Behaviour therapy improves communications and behavioral functioning in children with
autistic symptoms. Neuro-feedback is a noninvasive approach shown to enhance neurore‐
gulation and metabolic function in autistic spectrum disorder [50].
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Biological therapies
There are, so called biological therapies (“somewhat controversial”) such as secretin, oxyto‐
cin, gluten and casein free diet, vitamin B6, magnesium, dimethylglicyn, hyperbaric oxygen‐
ation therapy, melatonin. Melatonin administration in autistic spectrum disorders is
associated with improved sleep parameters, better daytime behaviour and minimal side ef‐
fects. Commonly used doses are 1-9 mg at night [51]. Vitamin B6 is being tested as a drug to
stimulate brain activity. It has been suggested that impairments associated with autism
spectrum disorders (ASD) may be partially explained by deficits of omega-3 fatty acids, and
that supplementation of these essential fatty acids may lead to improvement of symptoms
[52].
Stimulant drugs
Stimulants have been shown to reduce hyperactivity and improve focus, but they may cause
behavioral worsening, weight loss and stereotypes de novo. Drugs such as methylphenidate
are prescribed for attention deficit hyperactivity syndrome and have proven sufficiently
component in treating the similar symptoms of autism. Methylphenidate is stimulant com‐
monly prescribed for narcolpesy and tretament-resistant depression and attention deficit hy‐
peractivity disorder in children ages 6 to 17 and in adults. It increases norepinephrine and
dopamine by blocking their reuptake. The main goal of treatment of attention-deficit-hyper‐
activity is reduction of symptoms of inattentiveness, motor hyperactivity, and or impulsive‐
ness that disrupt social, school and occupational functioning. The common side effects are:
insomnia, headache, tics, irritability, anorexia, nausea, abdominal pain, weight loss, blurred
vision, and sometimes life-threatening or dangerous side effects as psychotic episodes, seiz‐
ures, palpitations, tachycardia, hypertension, rare neuroleptic malignant syndrome or cardi‐
ovascular abnormalities. Usual dosage range is 2.5 to 10 mg twice per day. Use in young
children sholud be reserved for specialist of child and adolescent psychiatry and it is not li‐
censed for children age under 6 years [28].
There is evidence that non-stimulant medication atomoxetine is effective. In both cases ad‐
verse events may be increased in this group requiring a slower titration and lower end
doses. Atomoxetine is selective norepinephrine reuptake inhibitor commonly prescribed for
attention deficit hyperactivity disorder in adults and children over 6 years old. Usual dosage
is 0.5 to 1.2 mg/kg per day in children up to 70 kg. Recommended target dose is 1.2 mg/kg
per day. It is not licensed for children with structural cardiac abnormalities or other serious
cardiac problems [28].
Secretin is a treatment that has received much media attention after reports of efficacy from a
small open studies but it controlled studies have failed to show any benefit. In autism also
same alternative treatments have been used, but none have shown some benefit [53].
Clonidine is antihypertensive and centrally acting alpha 2 agonist hypotensive agent, nonsti‐
mulant for attention deficit - hyperactivity disorder. It is commonly prescribed for attention
deficit - hyperactivity disorder, Tourette's syndrome, substance withdrawal, anxiety disor‐
ders, menopausal flushing etc. It is not licensed for children and children may be more sen‐
sitive to hypertensive effects of withdrawing treatment. Children may be more likely to
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experience central nervous depression with overdose and might be even exibit signs of tox‐
icity with 0.1 mg of clonidine. Usual dosage is 0.1 to 0.4 mg per day in divided doses. Cloni‐
dine is moderately prescribed drug for controlling hypertensive behaviour in autistic
children [28]. Other treatment options are: stem cells therapy, sensory-motor therapy, audi‐
tory integration therapy, sensory integration therapy and music therapy.
3. Conclusion
The decision to use medications early in the treatment plan for children with autism may be
a long-lasting good decision.
Antipsychotics as drugs are intended primarily for the treatment of adult patients with psy‐
chotic disorders, but showed the favorable effects on the symptoms in autistic children, es‐
pecially risperidone. Risperidone has been approved by the US Food and Drug
Administration for the symptomatic treatment of irritability (including symptoms of aggres‐
sion toward others, deliberate self-injuries, temper tantrums, and quickly changing moods)
in children and adolescents with autistic disorder.
Some studies suggest that the earlier use of antipsychotics in autistic children may have pro‐
tective effect on IQ, which further justifies the use of these drugs in early childhood [18]. Re‐
search on the use of risperidone in the treatment of autistic disorders among children in
Croatia are rare, given the limited use of risperidone in children younger than 15 years, the
question arises about the need to expand the scope of application of risperidone in younger
age groups.
Also, it may be worth to explore some alternative treatments, such as behavioural interven‐
tions, to try to avoid long-term medications. Also it is important to known that although
these psychotropic medications have many beneficial effects, they all come with some risk in
terms of adverse effects. It is well established that the early detection and treatment of side
effects helps reduce their long-term adverse effects on health. Family members are the ones
most likely to recognize those reactions such as: weight gain or fatigue. Also it is need for
psychoeducational programs for families or individuals with autism that teach parents
about medications and the signs and symptoms of potential side effects.
Atypical antipsychotic agents are widely used psyscopharmacological interventions for au‐
tism spectrum disorders and among them risperidone has demonstrated considerable bene‐
fits in reducing several behavioral symptoms associated with autism spectrum disorders.
Althought risperidone has several adverse effects, most are manageable or extremely rare.
An exception is rapid weight gain, which is common and can create significant health prob‐
lems [54]. Aripiprazole, a third generation of atypical antipsychotics, is relatively new drug
that has a unique mechanism of action different from other antypshotices. After treatment
with aripiprazole children showed less irritability, hyperactivity and stereotypes (repetitive,
purposeless actions). Notable side effects must be considered such as weight gain, sedation,
drooling and tremor [55].
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Autism comprises a clinically heterogeneous group of disorders-named „autism spectrum
disorders“ ASD. They share common features or impaired social relationships, impaired
language and communications, and repetative behaviours or a narrow range of interests.
Management of an autism involves educational, behavioral and medical therapies to pro‐
mote conversational language and social interactions while mitigating repetitive self-stimu‐
latory behaviours, tantrums, aggression and self-injuries behaviours. Medications, especially
atypical antipsychotics can ameliorate specific symptoms such as aggressive or self-injured
behaviour. Children treated early can usually be taught, to varying degrees, to communi‐
cate, recognize and respond to social interactions, developing imaginative play, and curb all
consuming repetative self-stimulatory behaviors [56]. Although most children with autism
are healthy, evidence is mounting that medical disorders have a significant effect on behav‐
iours, level of functioning and response to educational therapies. Sensory issues including a
blunted pain response, inability to tell others when they are uncomfortable and poor toler‐
ance of medical evaluations can lead to suboptimal medication care. The use of medications
has increased as newer medications, especially the atypical antipsychotics, which affect both
serotonin and dopamine systems and serotonin reuptake inhibitors (SRIs) which modulate
the serotonin system, have been studied in children. In 1997. year the National institute of
Mental Health Research Units on Pediatrics Psychopharmacology Autism Network investi‐
gated the safety and efficacy of drugs for treating the behaviours associated with autism.
Some of conclusions are: no medications are autism specific, marked differences exist in the
efficacy of drugs in adults vs. children, individual antipsychotics medications within the
same class may differ with respect to their potency and side effect profile, affected individu‐
als may respond differently to the same medication, medication management should be in‐
tegrated into family centered, multi-modal behavioral and educational program. Typically,
first line treatment for children with autism include psychosocial treatments and education‐
al interventions with the goal of maximizing language acquisition, improving social and
communications skills and extinguishing of maladaptive behaviours. Currently there are no
available standard medication treatments, addressing the core symptoms of autism. There
are no pharmacological treatments currently approved by US Food and Drug Administra‐
tion for autism. When used, pharmacological interventions usually target specific symp‐
toms, accompanying the core symptoms, and severely impairing the individual’s
functioning, often not allowing for „first line“ educational and behavioral interventions to
take place (aggression, self-injurious behavior, compulsive rituals, low frustration tolerance
with explosive outbursts, hyperactivity). The newer psychotropics, ecpecially the atypical
antipsychotics and the selective serotonin reuptake inhibitors (SSRIs) have more benign side
effects profiles than older agents [57]. Despite increased support for pediatric psychotropic
use, there is a need for more long-term safety and efficacy studies of existing medications
and newer, safer, and more effective agents with fewer side effects for the pharmacological
treatment of all childhood disorders in which aggression is prominent. Prescription of anti‐
psychotics drugs requires careful monitoring because of the safety risks and the likelihood
of a long-term use.
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Drug administration should be initiated at low dosages and subsequent dosage changes
sholud be based on tolerability and clinical response. Also children using risperidone may
need to be monitored more often than adults.
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